Hepatocellular carcinoma
CHUR Of Besançon is involved in clinical research for patients with locally advanced, metastatic, or unresectable hepatocellular carcinoma, with attention to disease control in advanced liver cancer.
- Hepatocellular carcinoma
- Unresectable liver cancer
- Advanced solid tumours
The sponsor’s research activity is centered on a single active trial in this indication, reflecting a focused clinical interest in challenging hepatic malignancies.
Immunotherapy and immune-based cancer treatment
The clinical programme includes investigation of immune checkpoint inhibition alongside a cancer vaccine strategy, with interest in treatment approaches that engage CD4-Th1 immune responses in hepatocellular carcinoma.
- Immune checkpoint therapy
- Cancer vaccine
- CD4-Th1 immune activation
This area of research links immuno-oncology with liver cancer management in patients not eligible for surgical resection.
Anti-angiogenic therapy
Research activity also involves treatment strategies incorporating bevacizumab, with emphasis on tumour-associated angiogenesis in advanced liver cancer.
- Bevacizumab
- Angiogenesis inhibition
- Tumour vascular targeting
The sponsor’s interest in this domain is tied to combined approaches for patients with difficult-to-treat hepatocellular carcinoma.
Clinical oncology and treatment response assessment
The trial landscape includes evaluation of objective response in advanced cancer care, with focus on measurable tumour outcomes in unresectable hepatocellular carcinoma.
- Objective response rate
- Tumour response assessment
- Advanced oncology care
Activity is concentrated in a French hospital setting with collaboration across multiple research sites supporting oncology-focused clinical investigation.
